SUDHIN BIOPHARMA COMPANY

Biotech · Private

Compact membrane-free cell settler device for selective removal of dead cells and debris from perfusion bioreactor culture while recycling live cells

sudhinbio.com →
Grants
$375K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel Compact Cell Settler for Perfusion Cultures of Microbial Cells$150,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel compact cell settlers for high cell density perfusion cultures of mammalian cells$225,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2694Sangamo Therapeutics——
2695ARMA BIO, INC.——
2696IGE THERAPEUTICS, INC.——
2697SUDHIN BIOPHARMA COMPANY——
2698MC1R VENTURES LLC——
2699SpinCeutica, Inc.——
2700VOVA IDA THERAPEUTICS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.